# US 2010/0248211 A1 · Method for analysis of hepatitis b virus s antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0248211 A1
- Document ID: US20100248211A1
- Status: Published application
- Kind: A1
- Application number: 12/447,806
- Filed: 2007-10-30
- Published: 2010-09-30
- Earliest claimed: 2006-10-30
- Assignees: Advanced Life Science Institute, Inc.
- Inventors: Naoko Matsubara; Yasuhiro Sugamata; Osamu Kusano; Noriko Shirata
- Web page: https://patentgrep.com/patent/US20100248211A1

## CPC

- G01N 33/5764: {Hepatitis B surface antigen}
- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

An object of the present invention is to enable to accurately quantify HBs antigen in the samples for which measured values are low or false-negative results by the conventional assaying method of HBs antigen. In the method of assaying HBs antigen according to the present invention, at least one inner capture probe that binds to a first inner region peptide consisting of 26th to 80th amino acid residues of HBs antigen and at least one outer capture probe that binds to a second outer region peptide consisting of 98th to 156th amino acid residues of HBs antigen are used as capture probes; and at least one inner detection probe which binds to the first inner region and at least one outer detection probe which binds to the second outer region are used as detection probes.

## Claims

### Claim 1

A method for assaying hepatitis B virus surface (HBs) antigen, characterized by using as capture probes at least one inner capture probe which binds to a first inner region peptide of HBs antigen and at least one outer capture probe which binds to a second outer region peptide of HBs antigen; and using as detection probes at least one inner detection probe which binds to said first inner region and at least one outer detection probe which binds to said second outer region.

### Claim 2 (depends on 1)

The method for assaying HBs antigen according to claim 1, wherein the epitope to which said inner capture probe binds and the epitope to which said inner detection probe binds are different, and the epitope to which said outer capture probe binds and the epitope to which said outer detection probe binds are different.

### Claim 3 (depends on 1, 2)

The method for assaying HBs antigen according to claim 1 or 2, wherein said inner capture probe binds to a peptide consisting of 51st to 60th amino acids in the amino acid sequence shown in SEQ ID NO: 1; said outer capture probe binds to a peptide consisting of 111th to 130th amino acids in the amino acid sequence shown in SEQ ID NO: 1; said inner detection probe binds to a peptide consisting of 51st to 69th amino acids in the amino acid sequence shown in SEQ ID NO: 1; and said outer detection probe binds to a peptide consisting of 98th to 156th amino acids in the amino acid sequence shown in SEQ ID NO: 1.

### Claim 4 (depends on 1)

The method for assaying HBs antigen according to claim 1, wherein said probes are monoclonal antibodies or fragments thereof.

### Claim 5 (depends on 4)

The method for assaying HBs antigen according to claim 4, wherein said inner capture monoclonal antibody is selected from the group consisting of FERM BP-10117 antibody, FERM BP-10702 antibody, FERM BP-10700 antibody and FERM BP-10698 antibody; said inner detection monoclonal antibody is selected from the group consisting of FERM BP-10117 antibody, FERM BP-10702 antibody, FERM BP-10700 antibody and FERM BP-10698 antibody; said outer capture monoclonal antibody is selected from the group consisting of FERM BP-10699 antibody, FERM BP-10703 antibody, FERM BP-10701 antibody and FERM BP-10697 antibody; said outer detection monoclonal antibody is selected from the group consisting of FERM BP-10699 antibody, FERM BP-10703 antibody, FERM BP-10701 antibody and FERM BP-10697 antibody; said inner capture monoclonal antibody and said inner detection monoclonal antibody are different antibodies; and said outer capture monoclonal antibody and said outer detection monoclonal antibody are different antibodies.

### Claim 6

A kit for assaying HBs antigen, characterized by comprising an antibodies-immobilized carrier comprising as capture probes at least one inner capture probe which binds to a first inner region peptide of HBs antigen and at least one outer capture probe which binds to a second outer region peptide of HBs antigen; and a reagent comprising as detection probes at least one inner detection probe which binds to said first inner region and at least one outer detection probe which binds to said second outer region.

### Claim 7

A mouse hybridoma deposited under an international accession No. FERM BP-10702, FERM BP-10698, FERM BP-10699, FERM BP-10703, FERM BP-10701, FERM BP-10700 or FERM BP-10697.

### Claim 8

A monoclonal antibody produced by a mouse hybridoma selected from the group consisting of the mouse hybridomas deposited under international accession Nos. FERM BP-10702, FERM BP-10698, FERM BP-10699, FERM BP-10703, FERM BP-10701, FERM BP-10700 and FERM BP-10697, respectively.
